|
|
Post by mnholdem on Jan 6, 2019 18:02:39 GMT -5
How many potential future investors in MannKind will see the JP Morgan presentation? That venue is for a selective audience. I simply think that a larger media presence would be beneficial.
A good friend once told me that more doctors read the Wall Street Journal than the total number of those who subscribe to the major medical journals (NEJM, Lancet, etc.).
The WSJ has a Medical section which publishes the latest news. My group of medical device companies regularly sends out new product releases and other developments to major (and several smaller) publishers in our fields. Sometimes they report the news, other times they don’t. We try to always give them an angle, an “eye-catcher” of sorts. We don’t tell these media outlets what to write, but often they piece the article together using the information and images we provide. We occasionally get a phone call from a reporter who is looking for a quote from our President or a Product Manager (we provide those too) but that’s rare. Most of the time the articles just encapsulate the info and images we provide.
|
|
|
|
Post by travis1953 on Jan 6, 2019 18:36:23 GMT -5
The buckets were presented at a Rodman Renshaw conference a couple of years ago:
"Bucket 1 [compounds already delivered to the lung]
Treprostinil1
Epinephrine2
Tobramycin
DNase
Bucket 2 [known compounds, non-lung delivery for acute use]
Glucagon
Rizatriptan
Sumatriptan
Palonosetron(5HT3 inhibitor)
Oxytocin
Bucket 3 [known compounds, non-lung delivery, chronic use]
Sildenafil
PTH
Oxyntomodulin
GLP-1
Bucket 4 [new chemical entities(NCEs)]
TPI-2088[new molecule for treating pain]
1FDA feedback indicates a safety and tolerability study in PAH patients will be required for approval
2FDA feedback indicates an efficacy study in anaphylaxis will be required for approval"
Has there ever been an explanation as to what TPI-2088 is?
|
|
|
|
Post by agedhippie on Jan 6, 2019 18:48:03 GMT -5
Why wasn't the information just added on the website in advance and then updated after the CC? I feel like they're saving it for JPM heathcare conference & won't update anything until then, but actually won't be surprised if it's lagged more.... ... why does it still say the company is listed on the TASE... |
|
|
|
Post by mango on Jan 6, 2019 19:53:22 GMT -5
The buckets were presented at a Rodman Renshaw conference a couple of years ago: "Bucket 1 [compounds already delivered to the lung] Treprostinil1 Epinephrine2 Tobramycin DNase Bucket 2 [known compounds, non-lung delivery for acute use] Glucagon Rizatriptan Sumatriptan Palonosetron(5HT3 inhibitor) Oxytocin Bucket 3 [known compounds, non-lung delivery, chronic use] Sildenafil PTH Oxyntomodulin GLP-1 Bucket 4 [new chemical entities(NCEs)] TPI-2088[new molecule for treating pain] 1FDA feedback indicates a safety and tolerability study in PAH patients will be required for approval 2FDA feedback indicates an efficacy study in anaphylaxis will be required for approval" Has there ever been an explanation as to what TPI-2088 is? Pain molecule |
|
|
|
Post by mnholdem on Jan 6, 2019 20:28:51 GMT -5
TPI-2088 is likely Torrey Pines Institute. Methods and compositions for treating painPatent number: 9610351 Abstract: Methods and compositions for treating pain are disclosed. The compositions are based on dry powders comprising microparticles of diketopiperazines and an analgesic active agent. The analgesic in the compositions comprises one or more peptide analgesics or derivatives thereof, which are administered to a subject using a pulmonary inhalation drug delivery system comprising a dry powder inhaler and the analgesic composition. The present compositions produce fewer side effects associated with current opioid therapy. Type: Grant Filed: February 13, 2015 Date of Patent: April 4, 2017 Assignees: MannKind Corporation, TORREY PINES INSTITUTE FOR MOLECULAR STUDIES Inventors: Andrea Leone-Bay, Richard A. Houghten, Joseph J. Guarneri, Grayson W. Stowell Source: patents.justia.com/patent/9610351 |
|
|
|
Post by mannmade on Jan 6, 2019 21:52:10 GMT -5
Yes MN as I recall this was a substitute for addictive pain killers. Actually in my opinion the killer app and biggest TS opportunity if as good as previously discussed. Drug was supposed to be non addictive and also very hard to overdose with. A perfect “fix” for the current epidemic.
|
|
|
|
Post by louaboardalia on Jan 6, 2019 22:05:03 GMT -5
Oxytocin question… During last night’s evening news, it was reported there has been an alarming increase in the death of women in America after having given birth. More than 2 years ago, a Gates Foundation Grant has awarded to the Mintaka Foundation who worked with Mannkind to develop an inhalable oxytocin as a means of preventing maternal death in childbirth in Africa. www.mintakafoundation.org/our-projects/maternal-health/On the Mintaka website, the following is noted: “Many deaths by bleeding could be prevented by an immediate intravenous injection of the drug oxytocin. However, oxytocin is unstable in warm climates and trained staff are not always available to give injections. With MannKind Corporation (USA), we have formulated oxytocin in a dry, stabilized form which can be loaded into a robust, very inexpensive, disposable inhaler, eliminating at the same time the need for injection. Administration by inhalation at last makes treatment possible outside centres with trained medical staff.” Given this earlier effort, and the acknowledgement this is a growing problem here as well, I am left wondering why oxytocin is not in Bucket 1, instead of Bucket 2. Does anyone know more about this? |
|
|
|
Post by mnholdem on Jan 7, 2019 5:52:00 GMT -5
Mintaka has been busy in other areas. In 2010 they got a $4.25 million grant to meet the costs of their flagship product 5P12-RANTES for HIV, which they developed over the next for years at the University of Nebaska-Lincoln. In 2014 ULN announced they'd successfully produced a drug compound to block HIV transmission in women. On Sept 6, 2018 Orion Biotechnology acquired the entire patent portfolio for an undisclosed amount.
Mintaka still lists that it's focused on "HIV/AIDS, prevention of maternal death in childbirth, and next-generation vaccines." It's second (death in childbirth) that involved MannKind, but I haven't found any recent development news.
The HIV project started with funding. I suspect that Mintaka hasn't been able to secure funding for its drug developed to use MannKind's inhaler. Perhaps they be able to use the proceeds from the sale of their HIV drug to continue the development of their remaining drug(s).
|
|
|
|
Post by #NoMoreNeedles on Jan 7, 2019 8:44:26 GMT -5
Let's hope MannKind is following through on its promise to launch a new corporate website that will accurately reflect their business and pipeline ambitions.
|
|
|
|
Post by mango on Jan 7, 2019 9:13:09 GMT -5
Yes MN as I recall this was a substitute for addictive pain killers. Actually in my opinion the killer app and biggest TS opportunity if as good as previously discussed. Drug was supposed to be non addictive and also very hard to overdose with. A perfect “fix” for the current epidemic. MannKind nicotine inhaler now more than ever, with new teen e-cig addition crisis. FDA is desperate for the help. Need teen specific smoking cessation products. FDA's Scott Gottlieb is at a standoff with Phillips Morris and JUUL. Smoking cessation is totally underrated and over looked. Huge market with poor-to subpar current therapies as competition. Exciting times |
|
|
|
Post by travis1953 on Jan 7, 2019 9:29:40 GMT -5
The buckets were presented at a Rodman Renshaw conference a couple of years ago: "Bucket 1 [compounds already delivered to the lung] Treprostinil1 Epinephrine2 Tobramycin DNase Bucket 2 [known compounds, non-lung delivery for acute use] Glucagon Rizatriptan Sumatriptan Palonosetron(5HT3 inhibitor) Oxytocin Bucket 3 [known compounds, non-lung delivery, chronic use] Sildenafil PTH Oxyntomodulin GLP-1 Bucket 4 [new chemical entities(NCEs)] TPI-2088[new molecule for treating pain] 1FDA feedback indicates a safety and tolerability study in PAH patients will be required for approval 2FDA feedback indicates an efficacy study in anaphylaxis will be required for approval" Has there ever been an explanation as to what TPI-2088 is? Pain molecule Yes, I noted that in the post, but I can find nothing regarding exactly what it is. Actually, the only place I find it mentioned is in that Rodman presentation. |
|
|
|
Post by #NoMoreNeedles on Jan 7, 2019 9:36:26 GMT -5
They have removed all previous presentation decks
|
|
|
|
Post by mango on Jan 7, 2019 9:50:49 GMT -5
Yes, I noted that in the post, but I can find nothing regarding exactly what it is. Actually, the only place I find it mentioned is in that Rodman presentation. Do a forum search on it, there's some posts that cover it in detail |
|
|
|
Post by louaboardalia on Jan 7, 2019 12:27:42 GMT -5
mnholdem...Thanks for the reply...sure looked promising, perhaps another Gates Foundation Grant will be forthcoming.
|
|
|
|
Post by sportsrancho on Jan 7, 2019 12:47:47 GMT -5
Yes MN as I recall this was a substitute for addictive pain killers. Actually in my opinion the killer app and biggest TS opportunity if as good as previously discussed. Drug was supposed to be non addictive and also very hard to overdose with. A perfect “fix” for the current epidemic. MannKind nicotine inhaler now more than ever, with new teen e-cig addition crisis. FDA is desperate for the help. Need teen specific smoking cessation products. FDA's Scott Gottlieb is at a standoff with Phillips Morris and JUUL. Smoking cessation is totally underrated and over looked. Huge market with poor-to subpar current therapies as competition. Exciting times 👍🏻 You mean one that doesn’t have chemicals, and doesn’t blow up:-) Go for it! |
|
